Home > Publications Database > Connector Hubs Accelerate the Spread of Tau Pathology in Alzheimer's Disease > print

001     283098
005     20251230135441.0
024 7 _ |a 10.1002/alz70862_109933
|2 doi
024 7 _ |a pmid:41433910
|2 pmid
024 7 _ |a pmc:PMC12724848
|2 pmc
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2025-01505
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hirsch, Fabian
|b 0
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Connector Hubs Accelerate the Spread of Tau Pathology in Alzheimer's Disease
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1767099251_6287
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Tau accumulation drives neurodegeneration and cognitive decline in Alzheimer's Disease (AD) and preclinical research suggests that tau spreads transsynaptically across connected neurons. We translated tau spreading models to human neuroimaging data, showing that tau pathology spreads from circumscribed epicenters to connected regions in AD, following the architecture of functional brain networks. To further determine whether the topology of brain networks influences tau spreading dynamics, we investigated whether functional hubs (i.e. regions with strong inter-regional connections) accelerate tau spread in AD. Specifically, we hypothesized that more efficient communication from tau epicenters towards hubs that cross-link large-scale brain networks (connector hubs) rather than hubs that interconnect neighboring regions (local hubs) accelerates amyloid-related tau accumulation and cognitive decline (Figure 1).Longitudinal tau/amyloid-PET and cognitive data from two independent cohorts covering the AD spectrum (ADNI/A4 n = 325/220) were analyzed to examine amyloid-driven spatiotemporal tau accumulation patterns and cognitive decline. Structural- and functional-connectivity templates from healthy controls were used to model the connectional efficiency of subject-level tau epicenters (i.e. 10% of brain regions with highest baseline tau-PET) towards connector/local hubs (Figure 2). Using robust regression, we then tested whether more efficient communication of subject-level tau epicenters to connector vs. local hubs accelerated global tau accumulation, cognitive decline, and tau dissemination across networks.Supporting our hypotheses, we found that the effect of higher baseline amyloid-PET on faster global tau-PET increases was moderated by more efficient communication of tau epicenters towards connector relative to local hubs (ADNI/A4: β = 0.31/0.40, p<0.001/0.03), such that subjects with stronger epicenter communication to connector hubs showed an amplified effect of amyloid on global tau accumulation rates (Figure 3A). The same interaction models also predicted faster cognitive decline (ADNI/A4: β = -0.49/-0.34, p<0.001/0.04, Figure 3B), and larger extents of tau dissemination across functional networks (ADNI/A4: β = 0.6/0.36, p<0.001/0.04). All p-values were FDR-corrected.Brain network topology shapes spatiotemporal tau accumulation rates and cognitive trajectories in AD. Specifically, stronger communication of tau epicenters with connector hubs that are characterized by widespread cross-network connections amplifies amyloid-related tau accumulation. This suggests that brain network architecture has a profound modulating impact on tau aggregation and disease progression in AD.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: metabolism
|2 MeSH
650 _ 2 |a Neuroimaging
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
700 1 _ |a Frontzkowski, Lukas
|b 1
700 1 _ |a Roemer-Cassiano, Sebastian
|b 2
700 1 _ |a Dehsarvi, Amir
|b 3
700 1 _ |a Steward, Anna
|b 4
700 1 _ |a Dewenter, Anna
|b 5
700 1 _ |a Biel, Davina
|b 6
700 1 _ |a Klonowksi, Madleen
|b 7
700 1 _ |a Zhu, Zeyu
|b 8
700 1 _ |a Gnoerich, Johannes
|0 P:(DE-2719)9001652
|b 9
|u dzne
700 1 _ |a Schöll, Michael
|b 10
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 11
|u dzne
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 12
|u dzne
700 1 _ |a Franzmeier, Nicolai
|b 13
773 _ _ |a 10.1002/alz70862_109933
|g Vol. 21 Suppl 8, no. Suppl 8, p. e109933
|0 PERI:(DE-600)2201940-6
|n Suppl 8
|p e109933
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/283098/files/DZNE-2025-1505.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/283098/files/DZNE-2025-1505.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)9001652
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 1
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21